Ishtiaq Rehman

Ishtiaq Rehman

Auto-generated profile, based on publicly available information

Ishtiaq Rehman

Sheffield University, Sheffield, United Kingdom

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in e-SPEN Journal
Verified
Journal Article
Closed access
AWAlicia E. Wooding
Alicia E. Wooding
IRIshtiaq Rehman
Ishtiaq Rehman

15 February 2006 in BJU International
Verified
Journal Article
Open access
PDF file
JCJ.W.F. Catto
J.W.F. Catto
SCSiobhan Cross
Siobhan Cross
JPJ. Phillips
J. Phillips
ALA. Leiblich
A. Leiblich
HLHing Leung
Hing Leung
IRI. Rehman
I. Rehman
In order to identify novel candidates associated with prostate cancer metastasis, we compared the proteomic profile of the poorly metastatic human prostate cancer cell line LNCaP, with its highly metastatic variant LNCaP‐LN3, by two‐dimensional gel electrophoresis. A major protein spot (pI of 5.9 and molecular weight of 37 KDa) was seen in LNCaP cells, but not in LNCaP‐LN3 cells and was identified as Lactate dehydrogenase‐B ( LDHB ), by tandem mass spectrometry. Furthermore, enzyme kinetic assays and Zymography showed a higher LDH enzyme activity in LNCaP cells compared with LNCaP‐LN3. Bisulfite modified DNA sequencing showed promoter hypermethylation in LNCaP‐LN3 cells but not in LNCaP, Du145, PC3, CWR22 or BPH45 cells. Treatment of LNCaP‐LN3 cells with 5’‐azacytidine caused re‐expression of LDHB transcripts. In tissues, LDHB promoter hypermethylation occurred at a higher frequency in prostate cancer 14/31 (45%), compared to adjacent non‐malignant or benign tissue, 2/19 (11%), ( P < 0.025). Immunohistochemistry showed a higher frequency of LDHB expression in benign or non‐malignant tissues, 59/ 73 (81%), compared to cancer cases, 3/53 (6%), ( P < 0.001). Absent LDHB expression was also seen in 7/7 (100%) cases of metastatic cancer in bone. Our data are the first to show loss of LDHB expression in prostate cancer, the mechanism of which appears to involve promoter hypermethylation.